Janus Henderson Group PLC lowered its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 18.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,908 shares of the medical device company’s stock after selling 1,086 shares during the quarter. Janus Henderson Group PLC’s holdings in Cardiovascular Systems were worth $211,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Piedmont Investment Advisors Inc. purchased a new position in shares of Cardiovascular Systems in the first quarter valued at approximately $340,000. PNC Financial Services Group Inc. lifted its position in shares of Cardiovascular Systems by 281,288.5% in the first quarter. PNC Financial Services Group Inc. now owns 73,161 shares of the medical device company’s stock valued at $2,830,000 after acquiring an additional 73,135 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Cardiovascular Systems in the first quarter valued at approximately $435,000. Mason Street Advisors LLC purchased a new position in shares of Cardiovascular Systems in the first quarter valued at approximately $432,000. Finally, Strs Ohio lifted its position in shares of Cardiovascular Systems by 32.7% in the first quarter. Strs Ohio now owns 22,300 shares of the medical device company’s stock valued at $862,000 after acquiring an additional 5,500 shares in the last quarter. Institutional investors own 94.33% of the company’s stock.
Several equities analysts have recently weighed in on the company. Lake Street Capital raised their target price on Cardiovascular Systems from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut Cardiovascular Systems from a “hold” rating to a “strong sell” rating and set a $47.00 price target for the company. in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, August 7th. Stifel Nicolaus cut Cardiovascular Systems from a “buy” rating to a “hold” rating and increased their price target for the company from $41.00 to $45.00 in a report on Tuesday, July 16th. They noted that the move was a valuation call. Finally, BidaskClub raised Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 17th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Cardiovascular Systems has an average rating of “Hold” and a consensus price target of $48.50.
NASDAQ:CSII opened at $48.97 on Wednesday. Cardiovascular Systems Inc has a one year low of $24.84 and a one year high of $51.74. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.83 and a current ratio of 4.25. The stock has a market cap of $1.68 billion, a PE ratio of -4,897.00 and a beta of 1.77. The stock has a 50 day moving average price of $46.23 and a 200 day moving average price of $40.37.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings results on Tuesday, August 6th. The medical device company reported $0.04 EPS for the quarter, meeting the consensus estimate of $0.04. The firm had revenue of $68.23 million during the quarter, compared to analysts’ expectations of $66.04 million. Cardiovascular Systems had a negative return on equity of 0.18% and a negative net margin of 0.10%. As a group, analysts predict that Cardiovascular Systems Inc will post 0.02 earnings per share for the current fiscal year.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc (NASDAQ:CSII).
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.